0001209191-17-053158.txt : 20170918
0001209191-17-053158.hdr.sgml : 20170918
20170918163533
ACCESSION NUMBER: 0001209191-17-053158
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170914
FILED AS OF DATE: 20170918
DATE AS OF CHANGE: 20170918
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: RITTER DALE
CENTRAL INDEX KEY: 0001244154
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36829
FILM NUMBER: 171090201
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INOTEK PHARMACEUTICALS CORP
CENTRAL INDEX KEY: 0001281895
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 91 HARTWELL AVE
STREET 2: 2ND FLOOR
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-676-2100
MAIL ADDRESS:
STREET 1: 91 HARTWELL AVE
STREET 2: 2ND FLOOR
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-09-14
0
0001281895
INOTEK PHARMACEUTICALS CORP
ITEK
0001244154
RITTER DALE
C/O INOTEK PHARMACEUTICALS CORPORATION
91 HARTWELL AVENUE 2ND FLOOR
LEXINGTON
MA
02421
0
1
0
0
Vice President, Finance
Common Stock
2017-09-14
4
M
0
12500
0.00
A
19827
D
Restricted Stock Units
2017-01-17
4
M
0
12500
0.00
D
Common Stock
12500
37500
D
Includes 7,327 shares of ITEK's common stock acquired under ITEK's Employee Stock Purchase Plan since the date of the Reporting Person's last Form 4 with Table I information. Of these 7,237 shares of ITEK's common stock, 2,591 shares were acquired on November 30, 2015 at the price of $4.83, 782 shares were acquired on May 31, 2016 at the price of $7.82, 1,765 shares were acquired on November 30, 2016 at the price of $5.44 and 2,189 shares were acquired on May 31, 2017 at the price of $1.45.
On September 14, 2017, 12,500 shares of Common Stock were issued in settlement of the restricted stock units described in footnote (4) below.
Each restricted stock unit represents a contingent right to receive one share of ITEK common stock.
The restricted stock units were issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan (the "Plan"). The restricted stock units vest in equal 25% tranches every 6 months over a 2 year period from the date of grant, subject to continued service through such dates.
/s/ Dale Ritter
2017-09-18